OBJECTIVE: The objective of this work is to perform a systematic review and meta-analysis of all randomized controlled trials comparing a single intravenous dose of palonosetron (PAL) 0.25 mg with other 5-HT(3)R in patients receiving moderately or highly emetogenic (MoHE) chemotherapy. METHODS: Several databases were searched, including MEDLINE, EMBASE, LILACS, and CENTRAL. The primary endpoints were the incidence of acute and delayed nausea and vomiting. The side effects of each treatment were analyzed. A subgroup analysis was performed to evaluate the influence of the use of corticosteroids. The results are expressed as risk ratio (RR) and the correspondent 95% confidence interval (CI). RESULTS: Five studies were included, with 2057 patients. PAL was compared with ondansetron, granisetron, and dolasetron. Patients in PAL group had less nausea, both acute (RR = 0.86; CI 95% = 0.76 to 0.96; p = 0.007) and delayed (RR = 0.82; CI95% = 0.75 to 0.89; p < 0.00001). They also had less acute vomiting (RR = 0.76; CI 95% = 0.66 to 0.88; p = 0.0002) and delayed vomiting (RR = 0.76; CI95% = 0.68 to 0.85; p < 0.00001). There were no statistical differences in side effects like headache (RR = 0.84; CI 95% = 0.61 to 1.17; p = 0.30), dizziness (RR = 0.40; CI 95% = 0.13 to 1.27; p = 0.12), constipation (RR = 1.29; CI 95% = 0.77 to 2.17; p = 0.33) or diarrhea (RR = 0.67; CI 95% = 0.24 to 1.85; p = 0.44). Patients receiving PAL presented less nausea and vomiting regardless of the use of corticoids. We found no statistical heterogeneity in the global analysis. CONCLUSION: PAL was more effective than the other 5-HT(3)R in preventing acute and delayed CINV in patients receiving MoHE treatments, regardless of the use of concomitant corticosteroids.
OBJECTIVE: The objective of this work is to perform a systematic review and meta-analysis of all randomized controlled trials comparing a single intravenous dose of palonosetron (PAL) 0.25 mg with other 5-HT(3)R in patients receiving moderately or highly emetogenic (MoHE) chemotherapy. METHODS: Several databases were searched, including MEDLINE, EMBASE, LILACS, and CENTRAL. The primary endpoints were the incidence of acute and delayed nausea and vomiting. The side effects of each treatment were analyzed. A subgroup analysis was performed to evaluate the influence of the use of corticosteroids. The results are expressed as risk ratio (RR) and the correspondent 95% confidence interval (CI). RESULTS: Five studies were included, with 2057 patients. PAL was compared with ondansetron, granisetron, and dolasetron. Patients in PAL group had less nausea, both acute (RR = 0.86; CI 95% = 0.76 to 0.96; p = 0.007) and delayed (RR = 0.82; CI95% = 0.75 to 0.89; p < 0.00001). They also had less acute vomiting (RR = 0.76; CI 95% = 0.66 to 0.88; p = 0.0002) and delayed vomiting (RR = 0.76; CI95% = 0.68 to 0.85; p < 0.00001). There were no statistical differences in side effects like headache (RR = 0.84; CI 95% = 0.61 to 1.17; p = 0.30), dizziness (RR = 0.40; CI 95% = 0.13 to 1.27; p = 0.12), constipation (RR = 1.29; CI 95% = 0.77 to 2.17; p = 0.33) or diarrhea (RR = 0.67; CI 95% = 0.24 to 1.85; p = 0.44). Patients receiving PAL presented less nausea and vomiting regardless of the use of corticoids. We found no statistical heterogeneity in the global analysis. CONCLUSION:PAL was more effective than the other 5-HT(3)R in preventing acute and delayed CINV in patients receiving MoHE treatments, regardless of the use of concomitant corticosteroids.
Authors: Ana Carolina Sepúlveda-Vildósola; Yadira Betanzos-Cabrera; Graciela Gascón Lastiri; Hugo Rivera-Márquez; Miguel Angel Villasis-Keever; Volkmar Wanzke Del Angel; Fernando Cerecedo Díaz; Enrique López-Aguilar Journal: Arch Med Res Date: 2008-08 Impact factor: 2.235
Authors: R Gralla; M Lichinitser; S Van Der Vegt; H Sleeboom; J Mezger; C Peschel; G Tonini; R Labianca; A Macciocchi; M Aapro Journal: Ann Oncol Date: 2003-10 Impact factor: 32.976
Authors: Kunal C Kadakia; Alexis D Leal; Drew K Seisler; Rui Qin; Kelliann C Fee-Schroeder; Darryl C Grendahl; Kristine M Sorgatz; Charles L Loprinzi Journal: Support Care Cancer Date: 2013-09-13 Impact factor: 3.603
Authors: Gary R Morrow; Lee Schwartzberg; Sally Y Barbour; Gianluca Ballinari; Michael D Thorn; David Cox Journal: J Community Support Oncol Date: 2014-07
Authors: Ronald Chow; David G Warr; Rudolph M Navari; May Tsao; Marko Popovic; Leonard Chiu; Milica Milakovic; Henry Lam; Carlo DeAngelis Journal: Support Care Cancer Date: 2018-05-23 Impact factor: 3.603
Authors: Mary Lou Affronti; Sarah Woodring; Karen Allen; John Kirkpatrick; Katherine B Peters; James E Herndon; Frances McSherry; Patrick N Healy; Annick Desjardins; James J Vredenburgh; Henry S Friedman Journal: Support Care Cancer Date: 2016-06-06 Impact factor: 3.603
Authors: Hyo Jung Kim; Sang Won Shin; Eun-Kee Song; Na-Ri Lee; Jun Suk Kim; Jin Seok Ahn; Hwan-Jung Yun; Yo-Han Cho; Keon Uk Park; Si-Young Kim; Joung Soon Jang; Sang-We Kim; Hyun Woo Lee; Se Ryeon Lee; Yang Soo Kim; Soon Nam Lee; Yoon Ho Ko; Hwa Jung Kim; Jin-Hyoung Kang Journal: Oncologist Date: 2015-10-28
Authors: J García Gómez; M E Pérez López; M Alonso Bermejo; Y Escobar Álvarez; J García Mata Journal: Clin Transl Oncol Date: 2013-09-10 Impact factor: 3.405
Authors: Mary Lou Affronti; Susan M Schneider; James E Herndon; Susan Schlundt; Henry S Friedman Journal: Support Care Cancer Date: 2014-02-26 Impact factor: 3.603